Patrick A. Baeuerle Ph.D.
Net Worth
Last updated:
What is Patrick A. Baeuerle Ph.D. net worth?
The estimated net worth of Dr. Patrick A. Baeuerle Ph.D. is at least $3,128,930 as of 8 Sep 2021. He owns shares worth $82,610 as insider, has earned $94,600 from insider trading and has received compensation worth at least $2,951,720 in Cullinan Oncology, Inc..
What is the salary of Patrick A. Baeuerle Ph.D.?
Dr. Patrick A. Baeuerle Ph.D. salary is $737,930 per year as Co-Founder & Acting Chief Scientific Officer of Biologics in Cullinan Oncology, Inc..
How old is Patrick A. Baeuerle Ph.D.?
Dr. Patrick A. Baeuerle Ph.D. is 67 years old, born in 1958.
What stocks does Patrick A. Baeuerle Ph.D. currently own?
As insider, Dr. Patrick A. Baeuerle Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cullinan Oncology, Inc. (CGEM) | Co-Founder & Acting Chief Scientific Officer of Biologics | 11,000 | $7.51 | $82,610 |
What does Cullinan Oncology, Inc. do?
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Patrick A. Baeuerle Ph.D. insider trading
Cullinan Oncology, Inc.
Dr. Patrick A. Baeuerle Ph.D. has made 2 insider trades in 2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 11,000 units of CGEM stock on 8 Sep 2021. As of 8 Sep 2021 he still owns at least 11,000 units of CGEM stock.
Cullinan Oncology key executives
Cullinan Oncology, Inc. executives and other stock owners filed with the SEC:
- Dr. Patrick A. Baeuerle Ph.D. (67) Co-Founder & Acting Chief Scientific Officer of Biologics
- Mr. Owen P. Hughes Jr. (50) Strategic Advisor